You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《異動股》先聲藥業(02096.HK)續漲逾12%價量齊創近七個月高
阿思達克 05-27 14:42
先聲藥業(02096.HK)三連升,繼昨天以逾半年大成交股價急漲10%突破野村上月首予目標價10.1元後,今早曾進一步升破瑞銀上月首予目標價10.8元,最高見10.88元,創近七個月高,現造10.5元,續漲逾12%,成交進一步增至1,445萬股,同創近七個月高,涉資逾1.5億元。

先聲是內地生物化學製藥集團,目前主要從事仿製藥業務。公司於以下專注戰略性治療領域擁有多元化的產品組合,分別有腫瘤、中樞神經系統及自身免疫疾病。股份於去年10月27日以每股13.7元來港上市。掛牌後股價一直「潛水」,最高僅於上市第四天高見11.68元已行人止步,去年11月27日曾跌至7.65元喘定回升。

瑞銀上月下旬指出,先聲正由藥品公司轉型至研發主導公司,當中以中央腫瘤科神經系統(CNS)和自身免疫性疾病為主,並相信公司具備豐富的藥物組合,料未來四年收入與純利年複合增長率分別為19%及21%,故首予其「買入」評級及目標價10.8元。此外,野村上月中也料先聲治療中樞神經系統疾病及自體免疫性疾病的藥物銷售增長,將帶動公司未來三年收入及盈利年複合率增長分別為20%及22%,故首予先聲藥業「買入」評級及目標價10.1元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account